Cancer Trial Design Flaw Sinks Compass Therapeutics Shares 61%
Summary
Compass Therapeutics' shares plummeted 61% after a Barrons.com report highlighted that its lead cancer drug, tovecimig, failed to meet its overall survival target in the COMPANION-002 Phase 2/3 study due to a critical trial design flaw. While the study met its progression-free survival endpoint, patient crossover confounded the overall survival data, rendering it statistically insignificant. This news provides crucial context to the company's earlier announcement today, which had emphasized "highly positive topline secondary endpoint data." The market's severe reaction underscores the significant setback for this clinical-stage biotech, as the inconclusive overall survival data for its lead asset creates substantial uncertainty for its path to commercialization. Investors will now closely watch the company's planned discussions with the FDA regarding the underlying data.
At the time of this announcement, CMPX was trading at $1.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $905.8M. The 52-week trading range was $1.61 to $6.88. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.